
Cognition Therapeutics, Inc.: shareholders and insiders
Price
$0.58
November 20, 2026Market cap $55M
What Ploutos Investor adds for Cognition Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Jun 22, 2026, from their own Form 4 filings.
Bought on the market
$32.5K
3 people
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $32.5K by 3 people·no sales
- 2025: no buys, no sales
- 2026: bought $32.5K by 3 people, no sales
- Jun 17, 2026Jack A. KhattarDirectorKind
- Jun 17, 2026Brett P MoniaDirectorKind
- Jun 17, 2026Peggy WallaceDirectorKind
- Jun 17, 2026Ellen B RichstoneDirectorKind
- Jun 17, 2026Aaron G.L. FletcherDirectorKind
- Apr 16, 2026Anthony CaggianoChief Medical OfficerKind
- Apr 16, 2026Lisa RicciardiCEO & PresidentKind
- Apr 16, 2026John Brendan DoyleChief Financial OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | Jack A. KhattarDirector | 25.0K | – | – | Form 4 | |
| Jun 17, 2026 | Brett P MoniaDirector | 25.0K | – | – | Form 4 | |
| Jun 17, 2026 | Peggy WallaceDirector | 25.0K | – | – | Form 4 | |
| Jun 17, 2026 | Ellen B RichstoneDirector | 25.0K | – | – | Form 4 | |
| Jun 17, 2026 | Aaron G.L. FletcherDirector | 25.0K | – | – | Form 4 | |
| Apr 16, 2026 | Anthony CaggianoChief Medical Officer | 10.0K | $1.11 | $11.1K | Form 4 | |
| Apr 16, 2026 | Lisa RicciardiCEO & President | 9,175 | $1.10 | $10.1K | Form 4 | |
| Apr 16, 2026 | John Brendan DoyleChief Financial Officer | 10.0K | $1.13 | $11.3K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 22, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by CGTX's officers and directors from 2021 up to November 21, 2025, 5 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Bios Memory Spv Iwith 21 more personsShare of class6.90%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Bios Memory Spv Iwith 21 more persons | 6.90% | 6.06M | Sep 23, 2025 | 13D/A |
Fell to 5% or less (1)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Pathstone Family Office0.00%Feb 4, 202513G
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Renaissance TechnologiesIn the quarter-15%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Renaissance Technologies | 587.2K | -15% | $600.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 7.40% of its shares outstanding were held short, -7.1% since the report before.
- Shares held short
- 7.04M
- 7.40%
- Since the report before7.58M on Sep 30, 2026
- -7.1%
- 9.9
- 707.9K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 91%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 296.8K
- Nov 15, 2023: Shares held short 240.2K
- Nov 30, 2023: Shares held short 197.5K
- Dec 15, 2023: Shares held short 150.9K
- Dec 29, 2023: Shares held short 71.1K
- Jan 12, 2024: Shares held short 117.3K
- Jan 31, 2024: Shares held short 145.4K
- Feb 15, 2024: Shares held short 100.5K
- Feb 29, 2024: Shares held short 126.7K
- Mar 15, 2024: Shares held short 228.1K
- Mar 28, 2024: Shares held short 150.2K
- Apr 15, 2024: Shares held short 220.3K
- Apr 30, 2024: Shares held short 172.3K
- May 15, 2024: Shares held short 122.5K
- May 31, 2024: Shares held short 210.6K
- Jun 14, 2024: Shares held short 180.7K
- Jun 28, 2024: Shares held short 208.1K
- Jul 15, 2024: Shares held short 214.8K
- Jul 31, 2024: Shares held short 1.77M
- Aug 15, 2024: Shares held short 647.5K
- Aug 30, 2024: Shares held short 914.9K
- Sep 13, 2024: Shares held short 709.9K
- Sep 30, 2024: Shares held short 531.4K
- Oct 15, 2024: Shares held short 490.7K
- Oct 31, 2024: Shares held short 815.7K
- Nov 15, 2024: Shares held short 723.0K
- Nov 29, 2024: Shares held short 2.68M
- Dec 13, 2024: Shares held short 1.47M
- Dec 31, 2024: Shares held short 1.81M
- Jan 15, 2025: Shares held short 624.9K
- Jan 31, 2025: Shares held short 523.9K
- Feb 14, 2025: Shares held short 222.8K
- Feb 28, 2025: Shares held short 2.11M
- Mar 14, 2025: Shares held short 1.42M
- Mar 31, 2025: Shares held short 1.54M
- Apr 15, 2025: Shares held short 911.9K
- Apr 30, 2025: Shares held short 912.9K
- May 15, 2025: Shares held short 1.34M
- May 30, 2025: Shares held short 757.9K
- Jun 13, 2025: Shares held short 1.54M
- Jun 30, 2025: Shares held short 1.94M
- Jul 15, 2025: Shares held short 7.41M
- Jul 31, 2025: Shares held short 5.32M
- Aug 15, 2025: Shares held short 6.23M
- Aug 29, 2025: Shares held short 9.21M
- Sep 15, 2025: Shares held short 9.00M
- Sep 30, 2025: Shares held short 7.14M
- Oct 15, 2025: Shares held short 8.44M
- Oct 31, 2025: Shares held short 7.41M
- Nov 14, 2025: Shares held short 7.34M
- Nov 28, 2025: Shares held short 6.40M
- Dec 15, 2025: Shares held short 6.44M
- Dec 31, 2025: Shares held short 5.79M
- Jan 15, 2026: Shares held short 6.90M
- Jan 30, 2026: Shares held short 7.24M
- Feb 13, 2026: Shares held short 7.38M
- Feb 27, 2026: Shares held short 7.14M
- Mar 13, 2026: Shares held short 7.00M
- Mar 31, 2026: Shares held short 6.85M
- Apr 15, 2026: Shares held short 7.32M
- Apr 30, 2026: Shares held short 7.98M
- May 15, 2026: Shares held short 7.76M
- May 29, 2026: Shares held short 6.42M
- Jun 15, 2026: Shares held short 7.51M
- Jun 30, 2026: Shares held short 7.07M
- Jul 15, 2026: Shares held short 9.68M
- Jul 31, 2026: Shares held short 8.93M
- Aug 14, 2026: Shares held short 7.13M
- Aug 31, 2026: Shares held short 7.86M
- Sep 15, 2026: Shares held short 7.74M
- Sep 30, 2026: Shares held short 7.58M
- Oct 15, 2026: Shares held short 7.04M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading44.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 44.2% of the shares in the reported trades were short sales, against 50.3% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 44.2%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 50.3%
- Change
- -6.1 pts
- Short sales a dayon average, of 233.9K shares
- 103.4K
- More than atof 3,666 US-listed companies, same days
- 30%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 34.6%
- Oct 15, 2026: Short sales 70.3%
- Oct 16, 2026: Short sales 66.6%
- Oct 19, 2026: Short sales 45.1%
- Oct 20, 2026: Short sales 50.7%
- Oct 21, 2026: Short sales 53.4%
- Oct 22, 2026: Short sales 43.3%
- Oct 23, 2026: Short sales 61.2%
- Oct 26, 2026: Short sales 37.5%
- Oct 27, 2026: Short sales 46.6%
- Oct 28, 2026: Short sales 32.2%
- Oct 29, 2026: Short sales 48.7%
- Oct 30, 2026: Short sales 45.8%
- Nov 2, 2026: Short sales 56%
- Nov 3, 2026: Short sales 56.2%
- Nov 4, 2026: Short sales 62.5%
- Nov 5, 2026: Short sales 32.9%
- Nov 6, 2026: Short sales 51%
- Nov 9, 2026: Short sales 26%
- Nov 10, 2026: Short sales 54.4%
- Nov 11, 2026: Short sales 34.2%
- Nov 12, 2026: Short sales 52.7%
- Nov 13, 2026: Short sales 37.3%
- Nov 16, 2026: Short sales 44.7%
- Nov 17, 2026: Short sales 37.4%
- Nov 18, 2026: Short sales 33%
- Nov 19, 2026: Short sales 41%
- Nov 20, 2026: Short sales 53%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Aaron G.L. FletcherDirectorDirectly6.08M
- Lisa RicciardiCEO & PresidentDirectly1.72M
- Anthony CaggianoChief Medical OfficerDirectly874.9K
- John Brendan DoyleChief Financial OfficerDirectly627.5K
- Peggy WallaceDirectorDirectly111.5K
- Ellen B RichstoneDirectorDirectly83.5K
- Jack A. KhattarDirectorDirectly73.5K
- Brett P MoniaDirectorDirectly73.5K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Aaron G.L. FletcherDirector | 6.08M | – | Jun 17, 2026 | Form 4 |
| Lisa RicciardiCEO & President | 1.72M | 38.9K | Apr 16, 2026 | Form 4 |
| Anthony CaggianoChief Medical Officer | 874.9K | – | Apr 16, 2026 | Form 4 |
| John Brendan DoyleChief Financial Officer | 627.5K | – | Apr 16, 2026 | Form 4 |
| Peggy WallaceDirector | 111.5K | – | Jun 17, 2026 | Form 4 |
| Ellen B RichstoneDirector | 83.5K | – | Jun 17, 2026 | Form 4 |
| Jack A. KhattarDirector | 73.5K | – | Jun 17, 2026 | Form 4 |
| Brett P MoniaDirector | 73.5K | – | Jun 17, 2026 | Form 4 |
A lower bound: it counts only the 8 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
| ETF | Weight in the fund | Holdings as of |
|---|---|---|
| IWCiShares Micro-Cap ETF | 0.02% | Jun 30, 2026 |
| VXFVanguard Extended Market Index Fund | 0.00% | Jun 30, 2026 |
| VTIVanguard Total Stock Market Index Fund | 0.00% | Jun 30, 2026 |
3 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 69
- Q4 2025: Managers 78
- Q1 2026: Managers 75
- Q2 2026: Managers 66
Institutional investors by quarter
The fund managers holding CGTX, quarter by quarter, from Q4 2021 to Q2 2025, 15 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 66 managers held 22.59M shares, worth $26M. During the quarter 4 opened a position, 13 closed one, 22 added and 10 trimmed.
The largest holders, Q2 2026
- BIOS Capital ManagementIn the quarter
- DavenportIn the quarter+47%
- Vanguard Capital ManagementIn the quarter+15%
- BlackRockIn the quarter+30%
- ChescapmanagerIn the quarter
- Geode Capital ManagementIn the quarter-1.1%
- Renaissance TechnologiesIn the quarter-38%
- Hilton Capital ManagementIn the quarter
- Vanguard Fiduciary TrustIn the quarter+9.6%
- CM ManagementIn the quarter+13%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BIOS Capital Management | 6.00M | $6.9M | |
| Davenport | 4.26M | +47% | $4.9M |
| Vanguard Capital Management | 3.44M | +15% | $4.0M |
| BlackRock | 1.26M | +30% | $1.5M |
| Chescapmanager | 997.0K | $1.1M | |
| Geode Capital Management | 910.0K | -1.1% | $1.0M |
| Renaissance Technologies | 693.3K | -38% | $797.3K |
| Hilton Capital Management | 549.0K | $631.3K | |
| Vanguard Fiduciary Trust | 508.2K | +9.6% | $584.5K |
| CM Management | 450.0K | +13% | $517.5K |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Cognition Therapeutics's filings show?
Who buys and sells is one part of Cognition Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have CGTX's insiders bought or sold?
From Jun 22, 2026 to Jun 22, 2026 Cognition Therapeutics's insiders reported no purchase or sale of shares on the market.
Which well-known managers hold CGTX?
1 of the managers we track held the shares on Sep 30, 2026. The largest position was Renaissance Technologies's, worth $600.0K.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.